The risk of long COVID has declined over the course of the pandemic, although it remains a persistent threat. Researchers from Washington University School of Medicine in St. Louis identified vaccination as a primary factor in reducing the risk of long COVID.
For people with relapsing-remitting multiple sclerosis (MS), a new study has found that the drug ofatumumab is more effective than teriflunomide at helping people across racial and ethnic groups reach a period of no disease activity. The study is published in the July 17, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary — a dendritic cell, a cytotoxic “killer” T cell, and a helper T cell, researchers at MSK and Baylor College of Medicine have found. The discovery could alter the way doctors administer immunotherapies.
Researchers at the University of Michigan Rogel Cancer Center found that a molecular mechanism, shared in cancer and pregnancy, that suppresses the immune system. Block this mechanism, called B7-H4, and the immune system revs up to slow cancer’s growth.
Certain pieces of DNA have been labeled as “selfish genetic elements” due to notions that they don’t contribute to a host organism’s survival. Instead, researchers have now discovered that these elements have been weaponized and play a crucial role by cutting off a competitor’s ability to reproduce.
Announcing Stephen Jameson, Ph.D., as 2024-2025 President of the American Association of Immunologists
The American Association of Immunologists (AAI) proudly announces Stephen Jameson, Ph.D., as its 2024-2025 president following his election to the office this past spring. Jameson, a distinguished immunologist, has been a member of the AAI Council since 2019 and will assume his new role on July 1, 2024.
Cedars-Sinai has published a roundup of its latest medical discoveries and faculty news for June 2024.
See how St. Jude researchers investigated Foxp3 function as a transcription cofactor in regulatory T cells in immune system activation and suppression.
Researchers discover that a cytokine called interleukin-12 (IL-12) acts like a switch to direct which antibody response B cells will generate.
That pile of soil you bought at the home improvement store may contain more than just dirt, according to new research from the University of Georgia. A new UGA study found high levels of multidrug-resistant fungi in commercially available compost, soil and flower bulbs. Aspergillus fumigatus is a widespread fungus that thrives in soil. But it also poses a serious risk to human health if inhaled. People with compromised immune systems are particularly vulnerable to the opportunistic fungus, facing a near 100% fatality rate if infected with a multidrug-resistant strain.
Georgia Tech bioengineer Ankur Singh and his team have developed a method to enhance adoptive T-cell therapy using nanowires to deliver miRNA to T-cells, preserving their naïve state for more effective disease-fighting. This innovative technique allows the T-cells to remain programmable and robust, offering a potential gamechanger for immunotherapies.
Low vaccination rates continue to create significant threats to public health for diseases such as whooping cough (pertussis), measles and COVID-19. Michigan's vaccination rates for recommended childhood immunizations have dropped to levels not seen in Michigan in more than a decade.
Research by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published today in the journal Cellular & Molecular Immunology.
"As an infectious diseases clinician, I've always been focused on research into pathogen-host interactions. We need to know why some people get sicker than others."
The researchers hope to one day target this T cell population via drug therapy. "These cells may be a very important target for treating ulcerative colitis and perhaps other autoimmune diseases..."
High response rates for patients with stage 4 lung cancer after anti-inflammatory drug added temporarily to immune checkpoint inhibitor therapy
Learn about immunology research from the St. Jude laboratory of Thirumala-Devi Kanneganti, PhD, that revealed the function of the NLRC5 innate immune sensor.
Checkpoint immunotherapy utilizing PD-1 blockade has become the standard of care for metastatic melanoma. While this treatment is effective in 40 percent of patients, the other 60 percent develop resistance, leading to tumor regrowth.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right